Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Negrier

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1991
Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastomaS Negrier, J Michon, D Floret, et al.
Cancer Treatment Reviews|June 1, 1989
Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patientsT Philip, A Mercatello, S Negrier, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 16, 2007
Breast cancer predictions by neural networks analysis: a comparison with logistic regressionV S Bourdès, S Bonnevay, P J G Lisboa, et al.
British Journal of Cancer|November 1, 1993
Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patientsT Philip, S Negrier, C Lasset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycinY Merrouche, S Negrier, C Bain, et al.
Bone Marrow Transplantation|October 1, 1991
Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot studyS Negrier, J Y Ranchere, I Philip, et al.
Bulletin Du Cancer|November 1, 1991
[Adverse effects of interleukin 2]A Ravaud, S Negrier, F Lakdja, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1989
Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre studyS Negrier, T Philip, G Stoter, et al.
Medical Oncology (Northwood, London, England)|September 17, 2009
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGETS Negrier, E Jäger, C Porta, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 1, 1995
Non-metastatic childhood ependymomasC Carrie, C Mottolese, E Bouffet, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1991
Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastomaS Negrier, J Michon, D Floret, et al.
Cancer Treatment Reviews|June 1, 1989
Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patientsT Philip, A Mercatello, S Negrier, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 16, 2007
Breast cancer predictions by neural networks analysis: a comparison with logistic regressionV S Bourdès, S Bonnevay, P J G Lisboa, et al.
British Journal of Cancer|November 1, 1993
Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patientsT Philip, S Negrier, C Lasset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycinY Merrouche, S Negrier, C Bain, et al.
Bone Marrow Transplantation|October 1, 1991
Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot studyS Negrier, J Y Ranchere, I Philip, et al.
Bulletin Du Cancer|November 1, 1991
[Adverse effects of interleukin 2]A Ravaud, S Negrier, F Lakdja, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1989
Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre studyS Negrier, T Philip, G Stoter, et al.
Medical Oncology (Northwood, London, England)|September 17, 2009
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGETS Negrier, E Jäger, C Porta, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 1, 1995
Non-metastatic childhood ependymomasC Carrie, C Mottolese, E Bouffet, et al.
Pageof 5